Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an update.
Cosmo Pharmaceuticals has achieved a significant milestone with the approval of its acne treatment, Winlevi®, in South Korea by the Ministry of Food and Drug Safety. This approval marks an important step in Cosmo’s global dermatology expansion, highlighting their commitment to innovative, patient-focused therapies. Winlevi® is notable for its unique mechanism as the first topical androgen receptor inhibitor in over four decades, offering a safe and effective treatment for acne vulgaris without systemic anti-androgen effects. The collaboration with Hyundai Pharm Co., Ltd. will facilitate the marketing and distribution of Winlevi® in South Korea, enhancing access to advanced acne treatment options for patients.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. The company is known for designing, developing, and manufacturing advanced solutions that address critical medical needs, improving the standard of care. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo operates globally with offices in the USA and Italy, and collaborates with leading pharmaceutical and MedTech companies.
Average Trading Volume: 21,217
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.